This therefore indicates that the degree of mitochondrial impairment in MeCP2-deficient cells is not as robust as seen in many mitochondrial diseases, which may well afford a greater chance for therapeutic success. The gene discussed is MECP2; the disease is inborn mitochondrial metabolism disorder.